Literature DB >> 22041561

[Downregulation of chromobox protein homolog 7 expression in multiple human cancer tissues].

Zhen-Po Guan1, Lian-Kun Gu, Bao-Cai Xing, Jia-Fu Ji, Jin Gu, Da-Jun Deng.   

Abstract

OBJECTIVE: To investigate the relationship between chromobox protein homolog 7 (cbx7) expression and the occurrence and development of colorectal carcinoma (CRC), gastric carcinoma (GC) and hepatocarcinoma (HCC) tissues.
METHODS: The samples of neoplastic tissues and the corresponding cutting-edge normal tissues from 22 cases of CRC, 20 cases of GC, 30 cases of HCC were surgically collected. Level of cbx7 mRNA was detected with a fluorescent quantitative RT-PCR assay, and the correlationship among expression of cbx7 mRNA, the patients' clinicopathologic features and the surviving time after surgery was analyzed.
RESULTS: The relative copy number of cbx7 mRNA in carcinomas and the normal tissues was 0.010 ± 0.015 vs 0.053 ± 0.042 for CRCs, 0.197 ± 0.195 vs 1.891 ± 1.254 for GCs, and 0.008 ± 0.008 vs 0.030 ± 0.021 for HCCs, respectively. Compared with the corresponding normal tissues, cbx7 expression was significantly downregulated in CRCs, GCs, and HCCs (t = -7.351, -5.417 and -6.680, respectively, P < 0.01). The expression of cbx7 mRNA in CRCs had significant differences not only between two age groups (the relative copy number of cbx7 mRNA in age > 55 group was 0.007 ± 0.015, but 0.017 ± 0.012 in age ≤ 55 group, t = -2.586, P = 0.022); but also between vascular embolus-positive and negative groups (the level of cbx7 mRNA in positive and negative group was 0.022 ± 0.021 vs 0.006 ± 0.011, t = -3.175, P = 0.010). The area under the receiver operating characteristics (ROC) curve is 0.769 (P = 0.033). when the Cut-off value of the relative copy number of cbx7 mRNA was 0.002 in CRCs. The values less-than 0.002 were defined as low expression. The CRC patients with low expression of cbx7 had a shorter overall survival time; whose 5 years survival rate was only 30.8% (4/13); while the rate was 77.8% (7/9) in high expression of cbx7 group. The difference had statistical significance (χ(2) = 4.329, P = 0.037). The similar differences could not be found among GC and HCC patients.
CONCLUSION: Downregulation of cbx7 expression was very common among multiple carcinomas cases, and the downregulation influenced the prognosis of CRC patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041561

Source DB:  PubMed          Journal:  Zhonghua Yu Fang Yi Xue Za Zhi        ISSN: 0253-9624


  8 in total

Review 1.  Polycomb protein family member CBX7 plays a critical role in cancer progression.

Authors:  Pierlorenzo Pallante; Floriana Forzati; Antonella Federico; Claudio Arra; Alfredo Fusco
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Authors:  Kristin A Rand; Chi Song; Eric Dean; Daniel J Serie; Karen Curtin; Xin Sheng; Donglei Hu; Carol Ann Huff; Leon Bernal-Mizrachi; Michael H Tomasson; Sikander Ailawadhi; Seema Singhal; Karen Pawlish; Edward S Peters; Cathryn H Bock; Alex Stram; David J Van Den Berg; Christopher K Edlund; David V Conti; Todd Zimmerman; Amie E Hwang; Scott Huntsman; John Graff; Ajay Nooka; Yinfei Kong; Silvana L Pregja; Sonja I Berndt; William J Blot; John Carpten; Graham Casey; Lisa Chu; W Ryan Diver; Victoria L Stevens; Michael R Lieber; Phyllis J Goodman; Anselm J M Hennis; Ann W Hsing; Jayesh Mehta; Rick A Kittles; Suzanne Kolb; Eric A Klein; Cristina Leske; Adam B Murphy; Barbara Nemesure; Christine Neslund-Dudas; Sara S Strom; Ravi Vij; Benjamin A Rybicki; Janet L Stanford; Lisa B Signorello; John S Witte; Christine B Ambrosone; Parveen Bhatti; Esther M John; Leslie Bernstein; Wei Zheng; Andrew F Olshan; Jennifer J Hu; Regina G Ziegler; Sarah J Nyante; Elisa V Bandera; Brenda M Birmann; Sue A Ingles; Michael F Press; Djordje Atanackovic; Martha J Glenn; Lisa A Cannon-Albright; Brandt Jones; Guido Tricot; Thomas G Martin; Shaji K Kumar; Jeffrey L Wolf; Sandra L Deming Halverson; Nathaniel Rothman; Angela R Brooks-Wilson; S Vincent Rajkumar; Laurence N Kolonel; Stephen J Chanock; Susan L Slager; Richard K Severson; Nalini Janakiraman; Howard R Terebelo; Elizabeth E Brown; Anneclaire J De Roos; Ann F Mohrbacher; Graham A Colditz; Graham G Giles; John J Spinelli; Brian C Chiu; Nikhil C Munshi; Kenneth C Anderson; Joan Levy; Jeffrey A Zonder; Robert Z Orlowski; Sagar Lonial; Nicola J Camp; Celine M Vachon; Elad Ziv; Daniel O Stram; Dennis J Hazelett; Christopher A Haiman; Wendy Cozen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-09-01       Impact factor: 4.254

3.  Expression and prognostic value of Chromobox family members in gastric cancer.

Authors:  Tao Ma; Ning Ma; Jia-Lin Chen; Fu-Xin Tang; Zhen Zong; Zhuo-Min Yu; Shuang Chen; Tai-Cheng Zhou
Journal:  J Gastrointest Oncol       Date:  2020-10

4.  Critical evaluation of Cbx7 downregulation in primary colon carcinomas and its clinical significance in Chinese patients.

Authors:  Xiang Zheng; Jing Zhou; Baozhen Zhang; Jun Zhang; James Wilson; Liankun Gu; Budong Zhu; Jin Gu; Jiafu Ji; Dajun Deng
Journal:  BMC Cancer       Date:  2015-03-18       Impact factor: 4.430

5.  Integrated genomic and methylation profile analysis to identify candidate tumor marker genes in patients with colorectal cancer.

Authors:  Guojun Huang; Wang Cheng; Fu Xi
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

6.  Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma.

Authors:  Kuan Hu; Lei Yao; Lei Zhou; Juanni Li
Journal:  Int J Gen Med       Date:  2022-03-04

7.  Evaluation of the prognostic value of CBXs in gastric cancer patients.

Authors:  Mengya He; Limin Yue; Haiyan Wang; Feiyan Yu; Mingyang Yu; Peng Ni; Ke Zhang; Shuaiyin Chen; Guangcai Duan; Rongguang Zhang
Journal:  Sci Rep       Date:  2021-06-11       Impact factor: 4.379

8.  Transcriptional expressions of Chromobox 1/2/3/6/8 as independent indicators for survivals in hepatocellular carcinoma patients.

Authors:  Gang Ning; Yan-Lin Huang; Li-Min Zhen; Wen-Xiong Xu; Qian Jiao; Fang-Ji Yang; Li-Na Wu; Yong-Yuan Zheng; Jie Song; Yen-Sheng Wang; Chan Xie; Liang Peng
Journal:  Aging (Albany NY)       Date:  2018-11-27       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.